Maraviroc Tarbis (Maraviroc)

Maraviroc blocks the CCR5 co‑receptor on CD4+ T‑cells, preventing the HIV‑1 envelope protein gp120 from binding. This inhibition stops the virus from entering the cell, thereby reducing replication of CCR5‑tropic HIV strains and contributing to viral suppression in patients receiving combination therapy.

The dosage of Maraviroc Tarbis is individualized by the prescribing clinician based on factors such as viral load, resistance profile, concomitant medications, and patient tolerance. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for Maraviroc in pregnancy and lactation are limited. It should be used only if the potential maternal benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike nucleoside reverse transcriptase inhibitors or protease inhibitors, Maraviroc targets the CCR5 co‑receptor, offering a distinct mechanism that can be valuable for patients with resistance to other classes. It is used in combination regimens to broaden antiviral activity and may be preferred when the virus is confirmed to be CCR5‑tropic.

Maraviroc Tarbis should be stored at ambient temperature, preferably below 25 °C, in its original container to protect from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Maraviroc is taken orally, usually with food to improve absorption. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include hepatotoxicity, severe allergic reactions such as anaphylaxis, depression or suicidal ideation, QT interval prolongation leading to cardiac arrhythmias, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should report any unusual symptoms promptly to their clinician.

Maraviroc is contraindicated in individuals with known hypersensitivity to maraviroc or any of its excipients. It should also be avoided in patients with severe liver impairment or those taking strong CYP3A inducers that would markedly reduce drug exposure, unless dose adjustments are made under medical supervision.